Compare Citius Pharmaceuticals Inc (CTXR) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs NRG Energy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while NRG Energy Inc trades at $120.63 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 1240.9× Citius Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.61% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NRG | |
|---|---|---|
Market Cap | $20.01M | $24.83B |
Sector | Health | Utilities |
52-Week High | $1.82 | $184.03 |
52-Week Low | $0.48 | $117.04 |
Enterprise Value | $16.23M | $48.79B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
NRG Energy trades at $120.97, up 1.73% today, with a bearish technical signal despite oversold RSI levels near support at $119. The company reported Q2 2026 EPS of $1.49, missing estimates of $1.69, but revenue grew 11% year-over-year, driven by cost controls and a strategic 1.2 GW Texas data-center power project. Fundamentals show a P/E of 30.76 and ROE of 26.77%, though net margin is thin at 2.56%.
Outlook is mixed: analyst consensus is bullish with a $207.83 price target (69% buy ratings), citing growth from data-center demand, but risks include rising interest costs, high leverage (debt-to-assets at 56.42% in 2025), and earnings misses. The stock offers a 1.6% dividend yield, but investors face volatility from execution risks in expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
